Agilent Life Sciences and Diagnostics Markets Group (LDG) (since 11/24)

https://www.agilent.com

Agilent Technologies Inc. (NYSE: A) [25 Nov 2024] announced a new organizational structure to accelerate the company's operational transformation to drive higher growth through a market-focused, customer-centric enterprise strategy. The new structure, including new leadership roles, takes effect immediately. The New Structure The new structure organizes Agilent's businesses according to its end markets and customers. It will enable closer collaboration among the business groups and better execution on cross-division, customer-first priorities. Below are the three new business groups: > Life Sciences and Diagnostics Markets Group (LDG) represents 38% of Agilent's revenue and is primarily focused on Agilent's pharma, biopharma, clinical, and diagnostics end markets. LDG provides a comprehensive portfolio of leading technology platforms and solutions to serve Agilent customers' value chain — including research and discovery, development and scale-up, production of therapeutics, and development of critical cancer diagnostics. LDG includes liquid chromatography and mass spectrometry instrument platforms, cell and biomolecular analysis, specialized CDMO services, pathology, companion diagnostics, and genomics. > Applied Markets Group (AMG) represents 20% of Agilent's revenue and is primarily focused on the food, environmental, forensics, chemicals, and advanced materials markets AMG will focus on growing Agilent's leadership in these markets and accelerating growth in new areas of the market. AMG includes gas chromatography and mass spectrometry, spectroscopy, and vacuum technology platforms. > Agilent CrossLab Group (ACG) represents 42% of Agilent's revenue and is focused on supporting our customers in all our end markets. ACG will accelerate and strengthen customer connections across all Agilent end markets. The group is uniquely positioned to leverage its comprehensive portfolio and capabilities. This will further enhance the installed base of instruments with targeted workflows and applications that drive critical outcomes and productivity in labs. ACG includes services, software and informatics, automation, and consumables. Business Group Leadership > Simon May will serve as president of LDG. Simon recently served as president of the Diagnostics and Genomics Group (DGG). Prior to joining Agilent earlier this year, Simon was executive vice president and president of the Life Science Group at Bio-Rad Laboratories. > Mike Zhang has been promoted to president of AMG. Most recently, Mike was vice president and general manager of our gas chromatography and mass spectrometry product line. Mike is a 22-year veteran of Agilent. Phil Binns, former president of the Life Sciences and Applied Markets group (LSAG), will retire in April 2025 after supporting the transition to the new business group structure. > Angelica Riemann will continue to serve as president of ACG. Angelica is a 25-year veteran of Agilent and prior to her current role she served as vice president and general manager of ACG's Services Division. *

	Start	2024-11-25 restructured
	Industry	laboratory equipment and instruments
	Industry 2	molecular diagnostics
	Person	May, Simon (Agilent 202411– President Life Sciences + Diagnostics Markets Group joined earlier in 2024 before Bio-Rad)

	Region	Santa Clara, CA
	Country	United States (USA)
	City	n. a.
		Address record changed: 2025-01-04

Basic data	Employees	n. a.

		* Document for »About Section«: Agilent Technologies Inc.. (11/25/24). "Press Release: Agilent Announces New Organizational Structure to Support its Market-Focused Strategy". Santa Clara, CA.

		Record changed: 2025-01-04